Dr. Elizabeth Mittendorf on Predictive Biomarkers in Vaccine Treatment for Breast Cancer
Elizabeth Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, discusses discovering a predictive biomarker response in vaccine therapy for patients with breast cancer.
Elizabeth Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, discusses discovering a predictive biomarker response in vaccine therapy for patients with breast cancer. Mittendorf says this may be because the metastatic environment can be hostile, and moving the therapy to the neoadjvant setting may be the best route for these patients to see results.
Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer
May 16th 2024During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
